Lineage Cell Therapeutics Inc(LCTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.18 | Insider Own | 24.46% | Shs Outstand | 252.9M | Perf Week | 4.57% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | -65.86% | Insider Trans | - | Shs Float | 191.1M | Perf Month | 7.77% |
| Enterprise Value | 0.21B | PEG | - | EPS next Q | -0.03 | Inst Own | 26.71% | Short Float | 13.57% | Perf Quarter | -4.63% |
| Income | -0.03B | P/S | 19.92 | EPS this Y | 79.08% | Inst Trans | 2.31% | Short Ratio | 20.74 | Perf Half Y | -31.79% |
| Sales | 0.01B | P/B | 4.28 | EPS next 5Y | - | ROA | -32.75% | Short Interest | 25.93M | Perf YTD | -38.32% |
| Book/sh | 0.24 | P/C | 5.12 | EPS past 3/5Y | -21.3% -14.94% | ROE | -59.03% | 52W High | -50.72% ($2.09) | Perf Year | -39.77% |
| Cash/sh | 0.2 | P/FCF | - | Sales past 3/5Y | -0.33% 79.88% | ROIC | -51.81% | 52W Low | 16.74% ($0.88) | Perf 3Y | -8.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 23.17% | Gross Margin | 93.81% | Volatility(W/M) | 5.33% 6.41% | Perf 5Y | -54.82% |
| Dividend TTM | - | EV/Sales | 16.12 | Sales Y/Y TTM | 19.87% | Oper. Margin | -205.23% | ATR (14) | 0.06 | Perf 10Y | -59.42% |
| Dividend Ex-Date | - | Quick Ratio | 6.61 | EPS Q/Q | 77.21% | Profit Margin | -246.58% | RSI (14) | 55.45 | Recom | 1.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.61 | Sales Q/Q | -61.34% | SMA20 | 5.78% ($0.97) | Beta | 1.7 | Target Price | $5.5 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/6 | SMA50 | 1.2% ($1.02) | Rel Volume | 0.75 | Prev Close | $1.04 |
| Employees | 77 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -6.01% -41.97% | SMA200 | -22.54% ($1.33) | Avg Volume(3M) | 1.25M | Price | $1.03 |
| IPO | 1992/3/5 | Option/Short | Yes/Yes | Trades | 4469 | Volume | 937,738 | Change | -0.96% |
🧬 This is a clinical-stage biotech developing regenerative medicine therapies based on allogeneic cell transplantation. Headquartered in the US, the company holds a cell therapy pipeline targeting areas with significant unmet medical needs, such as retinal degeneration and spinal cord injuries, and is conducting late-stage clinical trials through collaborations with major pharmaceutical companies.
Over the past 1 year, on the lower side
51% below its 1-year high.
Traded less than usual. That is 75% of its average volume.
LCTX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +79.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,992. Peers typically go for $1,089.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -54.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 26.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #278 of 594 in the industry
Based on market cap of $260M.
ABEO#277 Abeona Therapeutics Inc $261M PER - LCTX#278 Lineage Cell Therapeutics Inc $260M PER - 
IMRX#279 Immuneering Corp $260M PER - 
CUVL#280 Clinuvel Pharmaceuticals Ltd ADR $260M PER 11.2 
FATE#281 Fate Therapeutics Inc $260M PER - 
FAQ
What kind of company is LCTX?
LCTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LCTX?
The market cap of LCTX is approximately $260M, ranking 3,805 within its sector.
What is the 52-week high and low for LCTX?
LCTX has recorded a 52-week high of $2.09 and a low of $0.88.
